In the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. The objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD.

Journal Section:
Editor's choice
Keywords:
Depression, Inflammation, Cytokines
1.
Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J: Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990;24:115-120.
[PubMed]
https://doi.org/10.1159/000119472
2.
Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-785.
[PubMed]
https://doi.org/10.1016/j.neubiorev.2011.12.005
3.
Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
[PubMed]
https://doi.org/10.1016/0278-5846(94)00101-M
4.
Dean B, Tawadros N, Scarr E, Gibbons AS: Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 2010;120:245-248.
[PubMed]
https://doi.org/10.1016/j.jad.2009.04.027
5.
Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J, Palha JA, Sousa N: IL-10 modulates depressive-like behavior. J Psychiatr Res 2008;43:89-97.
[PubMed]
https://doi.org/10.1016/j.jpsychires.2008.02.004
6.
Song C, Wang H: Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:760-768.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2010.06.020
7.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
[PubMed]
https://doi.org/10.1016/j.biopsych.2009.09.033
8.
Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
[PubMed]
https://doi.org/10.1007/978-0-585-37970-8_2
9.
Licinio J, Wong ML: The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317-327.
[PubMed]
https://doi.org/10.1038/sj.mp.4000586
10.
Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15:199-226.
[PubMed]
https://doi.org/10.1006/brbi.2000.0597
11.
Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M: Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 2001;105:165-174.
[PubMed]
https://doi.org/10.1016/S0165-1781(01)00338-9
12.
Liu Y, Ho RC, Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
[PubMed]
https://doi.org/10.1016/j.jad.2011.08.003
13.
Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-186.
[PubMed]
https://doi.org/10.1097/PSY.0b013e3181907c1b
14.
Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, Mirnics K: Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011;16:751-762.
[PubMed]
https://doi.org/10.1038/mp.2010.52
15.
Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B: Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012;10:66.
[PubMed]
https://doi.org/10.1186/1741-7015-10-66
16.
Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 2001;933:222-234.
[PubMed]
https://doi.org/10.1111/j.1749-6632.2001.tb05827.x
17.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
[PubMed]
https://doi.org/10.1038/nrn2297
18.
Brietzke E, Kapczinski F: TNF-α as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1355-1361.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2008.01.006
19.
Sakic B, Gauldie J, Denburg JA, Szechtman H: Behavioral effects of infection with IL-6 adenovector. Brain Behav Immun 2001;15:25-42.
[PubMed]
https://doi.org/10.1006/brbi.1999.0576
20.
Kwant A, Sakic B: Behavioral effects of infection with interferon-γ adenovector. Behav Brain Res 2004;151:73-82.
[PubMed]
https://doi.org/10.1016/j.bbr.2003.08.008
21.
Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M: In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:744-759.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2010.08.026
22.
Maes M, Galecki P, Chang YS, Berk M: A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:676-692.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2010.05.004
23.
Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW: Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013;18:692-699.
[PubMed]
https://doi.org/10.1038/mp.2012.144
24.
Hiles SA, Baker AL, de Malmanche T, Attia J: A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012;26:1180-1188.
[PubMed]
https://doi.org/10.1016/j.bbi.2012.06.001
25.
Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC: Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30-38.
[PubMed]
https://doi.org/10.1111/j.1525-1497.2005.00269.x
26.
Rugulies R: Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med 2002;23:51-61.
[PubMed]
https://doi.org/10.1016/S0749-3797(02)00439-7
27.
Liu H, Luiten PG, Eisel UL, Dejongste MJ, Schoemaker RG: Depression after myocardial infarction: TNF-α-induced alterations of the blood-brain barrier and its putative therapeutic implications. Neurosci Biobehav Rev 2013;37:561-572.
[PubMed]
https://doi.org/10.1016/j.neubiorev.2013.02.004
28.
Brydon L, Edwards S, Jia H, Mohamed-Ali V, Zachary I, Martin JF, Steptoe A: Psychological stress activates interleukin-1β gene expression in human mononuclear cells. Brain Behav Immun 2005;19:540-546.
[PubMed]
https://doi.org/10.1016/j.bbi.2004.12.003
29.
Jaremka LM, Lindgren ME, Kiecolt-Glaser JK: Synergistic relationships among stress, depression, and troubled relationships: insights from psychoneuroimmunology. Depress Anxiety 2013;30:288-296.
[PubMed]
https://doi.org/10.1002/da.22078
30.
Kiecolt-Glaser JK, Gouin JP, Hantsoo L: Close relationships, inflammation, and health. Neurosci Biobehav Rev 2010;35:33-38.
[PubMed]
https://doi.org/10.1016/j.neubiorev.2009.09.003
31.
Brietzke E, Kauer Sant'anna M, Jackowski A, Grassi-Oliveira R, Bucker J, Zugman A, Mansur RB, Bressan RA: Impact of childhood stress on psychopathology. Rev Bras Psiquiatr 2012;34:480-488.
[PubMed]
https://doi.org/10.1016/j.rbp.2012.04.009
32.
Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A: Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008;65:409-415.
[PubMed]
https://doi.org/10.1001/archpsyc.65.4.409
33.
Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M: Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 1996;48:503-506.
[PubMed]
34.
Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M: New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant and neuroprogressive pathways, and new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012;20:127-150.
[PubMed]
https://doi.org/10.1007/s10787-011-0111-7
35.
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, Magalhaes PV, Amminger P, McGorry P, Malhi GS: Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804-817.
[PubMed]
https://doi.org/10.1016/j.neubiorev.2010.10.001
36.
Moylan S, Maes M, Wray NR, Berk M: The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013;18:595-606.
[PubMed]
https://doi.org/10.1038/mp.2012.33
37.
Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E: Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett 2011;32:540-544.
[PubMed]
38.
Zou JY, Crews FT: TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: Neuroprotection by NFκB inhibition. Brain Res 2005;1034:11-24.
[PubMed]
https://doi.org/10.1016/j.brainres.2004.11.014
39.
Hanisch UK, Neuhaus J, Rowe W, Van Rossum D, Moller T, Kettenmann H, Quirion R: Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience 1997;79:799-818.
[PubMed]
https://doi.org/10.1016/S0306-4522(97)00040-7
40.
Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A: Anti-inflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 2011;61:592-599.
[PubMed]
https://doi.org/10.1016/j.neuropharm.2011.04.033
41.
Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, Gotoh L, Yonaha M, Ueda T, Hashioka S, Kanba S: Inhibitory effects of SSRIs on IFN-γ induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1306-1316.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2010.07.015
42.
Xia Z, DePierre JW, Nassberger L: Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology 1996;34:27-37.
[PubMed]
https://doi.org/10.1016/0162-3109(96)00111-7
43.
Ohgi Y, Futamura T, Kikuchi T, Hashimoto K: Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2013;103:853-859.
[PubMed]
https://doi.org/10.1016/j.pbb.2012.12.003
44.
Hannestad J, DellaGioia N, Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452-2459.
[PubMed]
https://doi.org/10.1038/npp.2011.132
45.
Ehrlich P: Das Sauerstoff-Bedürfniss des Organismus: Eine Farbenanalytische Studie. Berlin, Hirschwald, 1885.
46.
Takeshita Y, Ransohoff RM: Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 2012;248:228-239.
[PubMed]
https://doi.org/10.1111/j.1600-065X.2012.01127.x
47.
Capuron L, Miller AH: Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226-238.
[PubMed]
https://doi.org/10.1016/j.pharmthera.2011.01.014
48.
Plotkin SR, Banks WA, Kastin AJ: Comparison of saturable transport and extracellular pathways in the passage of interleukin-1α across the blood-brain barrier. J Neuroimmunol 1996;67:41-47.
[PubMed]
https://doi.org/10.1016/0165-5728(96)00036-7
49.
Banks WA, Kastin AJ, Broadwell RD: Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995;2:241-248.
[PubMed]
https://doi.org/10.1159/000097202
50.
Watkins LR, Goehler LE, Relton JK, Tartaglia N, Silbert L, Martin D, Maier SF: Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995;183:27-31.
[PubMed]
https://doi.org/10.1016/0304-3940(94)11105-R
51.
Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B: T-cell trafficking in the central nervous system. Immunol Rev 2012;248:216-227.
[PubMed]
https://doi.org/10.1111/j.1600-065X.2012.01140.x
52.
Borkowska P, Kucia K, Rzezniczek S, Paul-Samojedny M, Suchanek R, Owczarek A, Kowalczyk M, Fila-Danilow A, Kowalski J: Interleukin-1B promoter (-31T/C and -511C/T) polymorphisms in paranoid schizophrenia. Psychiatr Genet 2012;22:311.
[PubMed]
https://doi.org/10.1097/YPG.0b013e3283586274
53.
Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, van Veen T, Willemsen G, DeRijk RH, de Geus EJ, Hoogendijk WJ, Sullivan PF, Penninx BW, Boomsma DI, Snieder H, Nolen WA: Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 2011;16:516-532.
[PubMed]
https://doi.org/10.1038/mp.2010.38
54.
Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S: Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med 2011;41:997-1007.
[PubMed]
https://doi.org/10.1017/S0033291710001674
55.
Haastrup E, Bukh JD, Bock C, Vinberg M, Thorner LW, Hansen T, Werge T, Kessing LV, Ullum H: Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. J Affect Disord 2012;136:134-138.
[PubMed]
https://doi.org/10.1016/j.jad.2011.08.025
56.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-379.
[PubMed]
https://doi.org/10.1016/S0893-133X(99)00134-7
57.
Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M: Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord 2013;145:300-307.
[PubMed]
https://doi.org/10.1016/j.jad.2012.08.007
58.
Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997;42:349-358.
[PubMed]
https://doi.org/10.1016/S0006-3223(96)00365-4
59.
Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-162.
[PubMed]
https://doi.org/10.1038/npp.2011.205
60.
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH: Depression during pegylated interferon-α plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41-48.
[PubMed]
61.
Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999;156:837-841.
[PubMed]
62.
Raison CL, Miller AH: Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467-475.
[PubMed]
https://doi.org/10.1007/s11920-011-0232-0
63.
Vogelzangs N, Kritchevsky SB, Beekman AT, Newman AB, Satterfield S, Simonsick EM, Yaffe K, Harris TB, Penninx BW: Depressive symptoms and change in abdominal obesity in older persons. Arch Gen Psychiatry 2008;65:1386-1393.
[PubMed]
https://doi.org/10.1001/archpsyc.65.12.1386
64.
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG: Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-229.
[PubMed]
https://doi.org/10.1001/archgenpsychiatry.2010.2
65.
Nathan C: Epidemic inflammation: pondering obesity. Mol Med 2008;14:485-492.
[PubMed]
66.
Shelton RC, Miller AH: Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 2010;91:275-299.
[PubMed]
https://doi.org/10.1016/j.pneurobio.2010.04.004
67.
Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.
[PubMed]
https://doi.org/10.1038/sj.mp.4001805
68.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607-611.
[PubMed]
https://doi.org/10.1002/da.20589
69.
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B: Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90:179-185.
[PubMed]
https://doi.org/10.1016/j.schres.2006.11.016
70.
Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ, Riedel M: Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-124.
[PubMed]
https://doi.org/10.1016/j.schres.2010.04.015
71.
Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-1034.
[PubMed]
https://doi.org/10.1176/appi.ajp.159.6.1029
72.
Fields C, Drye L, Vaidya V, Lyketsos C, ADAPT Research Group: Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 2012;20:505-513.
[PubMed]
https://doi.org/10.1097/JGP.0b013e318227f4da
73.
Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006;21:227-231.
[PubMed]
https://doi.org/10.1097/00004850-200607000-00005
74.
Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E: Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009;24:277-286.
[PubMed]
https://doi.org/10.1002/hup.1014
75.
Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A: Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275-1277.
[PubMed]
https://doi.org/10.1111/j.1365-2133.2007.08205.x
76.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
[PubMed]
https://doi.org/10.1016/S0140-6736(05)67763-X
77.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH: A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41.
[PubMed]
https://doi.org/10.1001/2013.jamapsychiatry.4
78.
Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, Powell AM, Manierka MS, McIntyre RS: Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 2012;235:302-317.
[PubMed]
https://doi.org/10.1016/j.bbr.2012.07.026
79.
Brietzke E, Mansur RB, Zugman A, Carvalho AF, Macedo DS, Cha DS, Abilio VC, McIntyre RS: Is there a role for curcumin in the treatment of bipolar disorder? Med Hypotheses 2013;80:606-612.
[PubMed]
https://doi.org/10.1016/j.mehy.2013.02.001
80.
Asevedo E, Cunha GR, Zugman A, Mansur RB, Brietzke E: N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Rev Neurosci 2012;23:353-362.
[PubMed]
https://doi.org/10.1515/revneuro-2012-0039
81.
Kulkarni S, Dhir A, Akula KK: Potentials of curcumin as an antidepressant. Sci World J 2009;9:1233-1241.
[PubMed]
https://doi.org/10.1100/tsw.2009.137
82.
Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT: Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1660-1666.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2008.06.010
83.
Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT: Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:380-386.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2007.09.004
84.
Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ: The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005;518:40-46.
[PubMed]
https://doi.org/10.1016/j.ejphar.2005.06.002
85.
Smaga I, Pomierny B, Krzyzanowska W, Pomierny-Chamiolo L, Miszkiel J, Niedzielska E, Ogorka A, Filip M: N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:280-287.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2012.06.018
86.
Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T, Horiguchi J: Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:222-226.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2012.02.002
87.
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI: N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475.
[PubMed]
https://doi.org/10.1016/j.biopsych.2008.04.022
88.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M: N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011;33:374-378.
[PubMed]
https://doi.org/10.1590/S1516-44462011000400011
89.
Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS: Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 2012;10:91.
[PubMed]
https://doi.org/10.1186/1741-7015-10-91
90.
Swardfager W, Herrmann N, McIntyre RS, Mazereeuw G, Goldberger K, Cha DS, Schwartz Y, Lanctot KL: Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev 2013;37:911-929.
[PubMed]
https://doi.org/10.1016/j.neubiorev.2013.03.018
91.
Nowak G, Siwek M, Dudek D, Zieba A, Pilc A: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 2003;55:1143-1147.
[PubMed]
92.
Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, Huebinger RM, Barber RC, Trivedi MH: Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013;18:1119-1124.
[PubMed]
https://doi.org/10.1038/mp.2012.125
93.
Andreescu C, Glick RM, Emeremni CA, Houck PR, Mulsant BH: Acupuncture for the treatment of major depressive disorder: a randomized controlled trial. J Clin Psychiatry 2011;72:1129-1135.
[PubMed]
https://doi.org/10.4088/JCP.10m06105
94.
Qu SS, Huang Y, Zhang ZJ, Chen JQ, Lin RY, Wang CQ, Li GL, Wong HK, Zhao CH, Pan JY, Guo SC, Zhang YC: A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder. J Psychiatr Res 2013;47:726-732.
[PubMed]
https://doi.org/10.1016/j.jpsychires.2013.02.004
95.
McDonald JL, Cripps AW, Smith PK, Smith CA, Xue CC, Golianu B: The anti-inflammatory effects of acupuncture and their relevance to allergic rhinitis: a narrative review and proposed model. Evid Based Complement Alternat Med 2013;2013:591796.
[PubMed]
https://doi.org/10.1155/2013/591796
96.
Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, DeBar LL, Lynch FL, D'Angelo E, Hollon SD, Shamseddeen W, Iyengar S: Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA 2009;301:2215-2224.
[PubMed]
https://doi.org/10.1001/jama.2009.788
97.
Smit F, Ederveen A, Cuijpers P, Deeg D, Beekman A: Opportunities for cost-effective prevention of late-life depression: an epidemiological approach. Arch Gen Psychiatry 2006;63:290-296.
[PubMed]
https://doi.org/10.1001/archpsyc.63.3.290
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.